Cullinan Therapeutics (CGEM) grants 175,000-share stock option to CBO Corrine Savill

Rhea-AI Filing Summary

Cullinan Therapeutics, Inc. reported that Chief Business Officer Corrine Savill received a grant of stock options covering 175,000 shares of common stock. The options have an exercise price of $0.00 per share and vest over four years in equal monthly installments of one forty-eighth of the grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Savill Corrine

Role Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	175,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 175,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Savill Corrine

(Last) (First) (Middle)

C/O CULLINAN THERAPEUTICS, INC.

ONE MAIN STREET, SUITE 1350

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cullinan Therapeutics, Inc. [ CGEM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.44	02/18/2026		A		175,000		(1)	02/18/2036	Common Stock	175,000	$0	175,000	D

Explanation of Responses:

1. The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

	/s/ Jacquelyn Sumer, Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cullinan Therapeutics (CGEM) report for Corrine Savill?

Cullinan Therapeutics reported that Chief Business Officer Corrine Savill received a stock option grant for 175,000 shares. The award is classified as a grant or other acquisition and reflects equity-based compensation, rather than an open-market stock purchase or sale by the executive.

How many shares are covered by Corrine Savill’s new stock option at Cullinan Therapeutics (CGEM)?

The stock option granted to Corrine Savill covers 175,000 shares of Cullinan Therapeutics common stock. Following this grant, her derivative holdings from this option total 175,000 shares, subject to the specified vesting schedule that governs when the options become exercisable over time.

What is the vesting schedule for Corrine Savill’s Cullinan Therapeutics (CGEM) stock option?

The option vests over four years, with one forty-eighth of the shares vesting in equal monthly installments until the fourth anniversary of the grant. This structure gradually delivers exercisable rights, aligning the award with continued service over the full vesting period.

What transaction code applies to Corrine Savill’s Cullinan Therapeutics (CGEM) option grant?

The transaction is reported under code “A,” which indicates a grant, award, or other acquisition of a derivative security. This reflects the issuance of a new stock option to Corrine Savill rather than a market purchase or sale of existing common shares.

Is Corrine Savill’s new Cullinan Therapeutics (CGEM) option held directly or indirectly?

The filing classifies Corrine Savill’s ownership of the stock option as direct, using the ownership code “D.” This means the derivative security is held in her own name, not through an intermediary entity such as a trust, partnership, or family investment vehicle.

What role does Corrine Savill hold at Cullinan Therapeutics (CGEM) related to this Form 4?

Corrine Savill is identified as the Chief Business Officer of Cullinan Therapeutics. The reported Form 4 transaction describes an equity award in the form of a stock option, reflecting compensation linked to her executive position and ongoing service at the company.